EDIT vs KLAC · rev $32.3M vs P/E 55, rev $12.16B
Editas Medicine Inc (EDIT) versus KLA Corporation (KLAC) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported KLAC revenue for 2025-06-30 was $12.16B. Net income was $4.06B. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
EDIT currently screens at market cap $375.2M. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Not investment advice. Open the EDIT and KLAC stock pages for the full models.
Not investment advice.